R R

What Is Simponi?

Simponi is a prescription biologic medication containing golimumab, a monoclonal antibody that blocks tumor necrosis factor-alpha, or TNF-alpha. It is approved for selected inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Simponi is administered by subcutaneous injection using a prefilled syringe or autoinjector. Its approved indications and dosing schedules vary by condition and patient age or weight. Simponi differs from Simponi Aria, an intravenous golimumab product with separate prescribing instructions. Simponi can reduce inflammatory disease activity but does not cure the underlying condition. It carries boxed warnings for serious infections and malignancies.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Simponi?

Simponi is a prescription biologic medication containing golimumab, a monoclonal antibody that blocks tumor necrosis factor-alpha, or TNF-alpha. It is approved for selected inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Simponi is administered by subcutaneous injection using a prefilled syringe or autoinjector. Its approved indications and dosing schedules vary by condition and patient age or weight. Simponi differs from Simponi Aria, an intravenous golimumab product with separate prescribing instructions. Simponi can reduce inflammatory disease activity but does not cure the underlying condition. It carries boxed warnings for serious infections and malignancies.

read more about simponi ...

Copy this HTML:

Copy HTML Copied!

How Does Simponi Work?

Simponi binds to tumor necrosis factor-alpha, an inflammatory signaling protein involved in immune responses. Excessive TNF-alpha activity contributes to inflammation and tissue damage in certain autoimmune and immune-mediated diseases. Golimumab blocks TNF-alpha from interacting with its receptors, reducing inflammatory signals that affect the joints, spine, and intestinal lining. This can relieve symptoms and help control disease activity in eligible patients. Simponi does not permanently correct the immune abnormalities responsible for these conditions. Because TNF-alpha also participates in defending the body against infections, blocking its activity can increase susceptibility to tuberculosis, fungal infections, and other serious infections.

What Conditions Does Simponi Treat?

Simponi is approved for adults with moderately to severely active rheumatoid arthritis when used with methotrexate. It also treats active psoriatic arthritis in adults, alone or with methotrexate, and active ankylosing spondylitis in adults. Another indication is moderately to severely active ulcerative colitis in adults and pediatric patients weighing at least 15 kg. Ulcerative colitis treatment is considered when patients meet the labeled clinical criteria, including previous treatment response or intolerance. Simponi Aria has separate indications that should not be attributed automatically to subcutaneous Simponi. Before treatment, clinicians evaluate disease activity, tuberculosis and hepatitis B status, vaccination history, and other immune-suppressing medications.

How Is Simponi Administered?

Simponi is administered by subcutaneous injection, with dosing based on the indication. Adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis generally receive 50 mg once monthly. Rheumatoid arthritis treatment requires concomitant methotrexate. For ulcerative colitis, adults and pediatric patients weighing at least 40 kg receive 200 mg initially, 100 mg at week two, and 100 mg at week six and every four weeks thereafter. Pediatric patients weighing 15 kg to less than 40 kg receive 100 mg initially, followed by 50 mg at week two and every four weeks starting at week six. Patients or caregivers may administer injections after appropriate training. Screening and vaccination review are required before starting treatment.

What Are the Side Effects and Warnings of Simponi?

Common adverse effects include upper respiratory infections and injection-site reactions such as redness or discomfort. Simponi carries boxed warnings for serious infections, including tuberculosis, invasive fungal infections, and opportunistic infections, and for malignancies, including lymphoma. Hepatitis B reactivation, worsening heart failure, demyelinating disorders, reduced blood cell counts, and serious allergic reactions can also occur. Patients should not begin treatment during an active serious infection. Live vaccines should be avoided during therapy. Clinicians monitor for infection symptoms and other complications throughout treatment. Persistent fever, severe cough, unexplained weight loss, unusual bruising, new neurological symptoms, or difficulty breathing requires prompt medical evaluation.

Common Questions About Simponi

Is Simponi the same as golimumab?

Yes. Simponi contains golimumab, a TNF-alpha inhibitor used for selected inflammatory conditions.

Can Simponi treat ulcerative colitis in children?

Yes. Subcutaneous Simponi is approved for eligible pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis. Dosing depends on body weight.

Is Simponi the same as Simponi Aria?

No. Simponi is administered by subcutaneous injection, while Simponi Aria is given by intravenous infusion. Their approved indications and schedules differ.

Does Simponi increase the risk of tuberculosis?

Yes. TNF blockers can reactivate latent tuberculosis or increase susceptibility to serious infections. Tuberculosis screening is required before treatment.

References

DailyMed - SIMPONI (golimumab) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f86cb4a7-c358-4136-ae57-b32bda9bba00. Date Accessed November 10, 2026.

Golimumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548112/. Date Accessed November 10, 2026.

Golimumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a610010.html. Date Accessed November 10, 2026.

SIMPONI Prescribing Information. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f86cb4a7-c358-4136-ae57-b32bda9bba00&type=display. Date Accessed November 10, 2026.

Simponi. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/simponi. Date Accessed November 10, 2026.